| Project/Area Number |
24501340
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Tumor diagnosis
|
|---|
| Research Institution | Hamamatsu University School of Medicine |
|---|
Principal Investigator |
ONO TAKAAKI 浜松医科大学, 医学部附属病院, 助教 (40402276)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
OHNISHI Kazunori 浜松医科大学, 医学部附属病院, 教授 (80252170)
|
|---|
| Project Period (FY) |
2012-04-01 – 2015-03-31
|
| Project Status |
Completed (Fiscal Year 2014)
|
| Budget Amount *help |
¥3,380,000 (Direct Cost: ¥2,600,000、Indirect Cost: ¥780,000)
Fiscal Year 2014: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2013: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2012: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
|
|---|
| Keywords | 慢性骨髄性白血病 / BCR-ABL1点突然変異 / PCR-インベーダー法 / イマチニブ / BCR-ABL1点突然変異解析 / BCR-ABL1遺伝子点突然変異 / チロシンキナーゼ阻害剤 / 腫瘍診断学 / 薬物評価と予測 / 薬効評価と予測 |
|---|
| Outline of Final Research Achievements |
The association between BCR-ABL1 kinase domain mutation and therapeutic response was evaluated in patients with chronic myelogenous leukemia（CML) using both PCR-Invader assay and direct sequencing to establish standard method for screening of mutations. BCR-ABL1 KD mutations were detected in 1 patient of 19 newly diagnosed CML and 4 of 6 tyrosine kinase inhibitor (TKI) resistant CML.Among detected mutations,exon 8/9 35-bp insertion (BCR-ABL135INS mutation) was observed in 3 patients with newly diagnosed CML (n=1) or TKI resistant CML (n=2). Our result showed that CML with BCR-ABL135INS mutation had resistance for imatinib, while this mutation had favorable response to nilotinib. PCR-Invader assay is useful for screening of mutations, although we should be careful for the undetectability of BCR-ABL135INS mutation by using this assay.
|
